Clinical Trials
183 trialsA Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
A Study to Evaluate the Safety, Tolerability, PK and Efficacy of Hemay5087 in Patients With Advanced Solid Tumors
Ganzhou Hemay Pharmaceutical Co., Ltd
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
Boehringer Ingelheim
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase I Comparative Bioavailability Study
AstraZeneca
QTX3034 in Patients With KRAS G12D Mutation
Quanta Therapeutics
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
ORIC Pharmaceuticals
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Gilead Sciences
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
KEYNOTE-603
ModernaTX, Inc.
Study of AUBE00 in Patients With Solid Tumors
Chugai Pharmaceutical
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
Boehringer Ingelheim
DPTX3186 in Wnt Pathway Activated Solid Tumors
Dewpoint Therapeutics
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
A Study of DS3610a in Participants With Advanced Solid Tumor
Daiichi Sankyo
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
Tcelltech Inc.
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
Boehringer Ingelheim
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
Takeda
ATB-320-001A
Autotelicbio
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Incyte Corporation
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
Guangzhou Virotech Pharmaceutical Co., Ltd.
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
CytomX Therapeutics
Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16
Sound Biopharmaceuticals Ltd.
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
AstraZeneca
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
A Study of TAK-102 in Adult With Previously-Treated Solid Tumors
Takeda
A Study of TAK-103 in Adult With Solid Tumors
Takeda
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
Hoffmann-La Roche
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
Adcentrx Therapeutics
A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors
Heronova Pharmaceuticals
Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors
BPGbio
A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
Stemline Therapeutics, Inc.
A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body
Boehringer Ingelheim
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
BeiGene
Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer
Astellas Pharma Inc
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
Merck KGaA, Darmstadt, Germany
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
Shandong Boan Biotechnology Co., Ltd
An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
Astellas Pharma Inc